Medpace Holdings, Inc. $MEDP Shares Sold by Mutual of America Capital Management LLC

Key Points

• Mutual of America Capital Management LLC reduced its stake in Medpace Holdings, Inc. by 8.8%, now holding 11,722 shares valued at approximately $3.68 million.
• Medpace reported $3.86 EPS for the latest quarter, exceeding analysts' expectations, with revenue of $659.90 million, marking a year-over-year increase of 23.7%.
• Insiders have sold a total of 107,465 shares of Medpace stock in the last quarter, amounting to $49.72 million, with CEO August J. Troendle selling 36,196 shares.

Mutual of America Capital Management LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 8.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,722 shares of the company's stock after selling 1,137 shares during the period. Mutual of America Capital Management LLC's holdings in Medpace were worth $3,679,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in MEDP. GAMMA Investing LLC grew its holdings in Medpace by 37.1% during the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after acquiring an additional 83 shares in the last quarter. Moran Wealth Management LLC bought a new stake in shares of Medpace in the 1st quarter worth about $5,158,000. Bartlett & CO. Wealth Management LLC increased its position in shares of Medpace by 17.5% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 343 shares of the company's stock worth $105,000 after purchasing an additional 51 shares during the last quarter. Smith Group Asset Management LLC increased its position in shares of Medpace by 7.3% in the 1st quarter. Smith Group Asset Management LLC now owns 79,694 shares of the company's stock worth $24,282,000 after purchasing an additional 5,436 shares during the last quarter. Finally, Novem Group increased its position in shares of Medpace by 35.3% in the 1st quarter. Novem Group now owns 2,924 shares of the company's stock worth $891,000 after purchasing an additional 763 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Trading Up 9.1%

MEDP stock opened at $596.61 on Friday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $625.00. The company has a market capitalization of $16.76 billion, a price-to-earnings ratio of 41.72, a price-to-earnings-growth ratio of 3.39 and a beta of 1.40. The firm's 50-day moving average is $500.19 and its two-hundred day moving average is $389.01.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 81.62%. The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same period in the previous year, the firm earned $3.01 EPS. Medpace's revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Buying and Selling at Medpace

In related news, CEO August J. Troendle sold 36,196 shares of the business's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the sale, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. The trade was a 3.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the general counsel owned 10,343 shares in the company, valued at $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 107,465 shares of company stock valued at $49,720,216 over the last quarter. Company insiders own 20.30% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MEDP. TD Cowen reissued a "sell" rating and issued a $366.00 target price (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Jefferies Financial Group lifted their price target on shares of Medpace from $400.00 to $450.00 and gave the company a "hold" rating in a report on Tuesday, September 9th. Truist Financial lifted their price target on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Finally, Zacks Research lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Monday, September 22nd. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Medpace has an average rating of "Reduce" and an average target price of $430.60.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.